Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Total Current Liabilities (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Total Current Liabilities for 3 consecutive years, with $26.4 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Total Current Liabilities rose 132.44% year-over-year to $26.4 million, compared with a TTM value of $26.4 million through Sep 2021, up 132.44%, and an annual FY2020 reading of $14.2 million, up 192.37% over the prior year.
  • Total Current Liabilities was $26.4 million for Q3 2021 at Black Diamond Therapeutics, up from $23.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $26.4 million in Q3 2021 and bottomed at $4.9 million in Q4 2019.
  • Average Total Current Liabilities over 3 years is $14.1 million, with a median of $12.8 million recorded in 2020.
  • Peak annual rise in Total Current Liabilities hit 282.57% in 2021, while the deepest fall reached 132.44% in 2021.
  • Year by year, Total Current Liabilities stood at $4.9 million in 2019, then skyrocketed by 192.37% to $14.2 million in 2020, then surged by 85.41% to $26.4 million in 2021.
  • Business Quant data shows Total Current Liabilities for BDTX at $26.4 million in Q3 2021, $23.5 million in Q2 2021, and $18.7 million in Q1 2021.